Spike protein antibodies are immune proteins produced after a SARS-CoV-2 infection or COVID-19 vaccination that bind to the virus's spike glycoprotein. Antibodies targeting the spike's receptor-binding domain (RBD) can block the virus from attaching to host cells via ACE2 receptors and help neutralize infection.Chikhali Chinchwad